Dr. Manveen K Saluja is a Troy, Michigan based female rheumatologist who is specialized in Rheumatology. Active license number of Dr. Manveen K Saluja for Rheumatology is 4301056405 in Michigan. Dr. Manveen K Saluja treat joint disease similar to orthopedists but do not perform surgeries. She diagnose and treat diseases of joints, muscle, bones and tendons which includes arthritis, back pain, muscle strains, common athletic injuries and 'collagen' diseases.
Complete Profile:
Dr. Manveen K Saluja speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1386635084
NPI Enumeration Date:
02 Nov, 2005
NPI Last Update On:
14 Nov, 2018
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Manveen K Saluja are as mentioned below.
License Number
Specialization
State
Status
4301056405
Rheumatologist
Michigan
Primary
Other Medical Identifiers:
Other legacy medical identifiers associated with Dr. Manveen K Saluja such as Medicaid, Medicare PIN, NSC, UPIN etc. are mentioned as below.
Identifier
Type
State
Issuer
1106336322
Medicaid
Michigan
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1380 Coolidge Hwy, Ste 150 Troy, Michigan
Zip:
48084-7069
Phone Number:
248-677-4700
Fax Number:
248-655-0144
Patients can reach Dr. Manveen K Saluja at 1380 Coolidge Hwy, Ste 150, Troy, Michigan or can call to book an appointment on 248-677-4700. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.